Question 4

With respect to non-convulsive status epilepticus (NCSE):
a) Outline the challenges in the diagnosis of NCSE. (2.5 marks)
b) List five risk factors for NCSE. (2.5 marks)
c) Outline the principles of management for patients with suspected NCSE. (5 marks)

[Click here to toggle visibility of the answers]

College answer

Syllabus topic/section: 2.1.8 Neurological Intensive Care / Seizure disorders including status epilepticus: L1

Discussion: NCSE is a distinct clinical entity from status epilepticus. Candidates who acknowledged those nuances and addressed this in their answer were able to demonstrate the standard required. Candidates can ensure they cover breadth by considering the types of information used clinically when securing a diagnosis as history, examination and investigations all contribute to diagnostic reasoning. Answers with structure, (for example, in part a) using headings which could include practical, logistical and clinical challenges among others) were rewarded.
Better answers to part C addressed control of seizures, prevention of secondary injury, finding and treating precipitants and involved a strategy for de-escalation. Outline is a glossary term that is defined as ‘provide a summary of the important points’ which is more than a simple list. For parts A and B, the question asked for an outline and accordingly higher marks were awarded for structured, details answers. As an illustration, general comments about the importance of maintenance of MAP/normoxia/normoglycaemia did not gain marks unless they were contextualised as neuroprotective cares for the patient with NCSE.
It is expected that just listing anti-epileptics is not enough to demonstrate the standard of competence required at the level of a transitional fellow who will be entrusted with independent practice of the critically ill. More detail in terms of dosing considerations, an approach to drug interactions and ways to mitigate unintended consequences is needed.

Discussion

Challenges:

  • Distinguishable from convulsive SE by not involving motor cortex neurons, but also may be distinct in other ways, eg. potentially not a distinct disease process but rather a marker of severity of CNS dysfunction 
  • No clinical findings
  • No agreement on the diagnostic criteria by which to identify this condition.
  • What criteria we have are based on EEG, but EEG may not capture the epileptiform discharges if it is only performed during an interictal period
  • Even when EEG is available, EEG findings are frequently non-specific which should also be interpreted as features of encephalopathy

Risk factors:

  • Known epileptic with an acute infection
  • Recent convulsive seizures
  • Remote risk factors for seizures:
    • previous stroke
    • tumour
    • neurosurgery
    • dementia
    • multiple sclerosis
    • encephalitis or meningitis

Principles of management

  • Treatment of the underlying precipitant is essential
  • Controversy exists as to whether one should offer any treatment at all to the NSCE itself
  • It is unclear whether it causes neurological damage (animal data, mostly)
  • Guidelines are mostly extrapolated from convulsive SE, which means they may be too aggressive
  • Management should be reserved for patients in whom the added benefit of management has clear advantages (eg. decreased CNS oxyegnc consumption in TBI)
  • Prognosis is mostly determined by the prognosis of the underlying disease; management of patients with lower severity of underlying disease should therefore be more conservative
  • For pharmacotherapy, benzodiazepines are first line
  • Valproate, levitiracteam and lacosamide are second line
  • Seek to reduce threshold-lowering stimuli (eg. hyponatremia)
  • Antiepileptic therapy must be guided by serial or continuous EEG, as clinical features are subtle and difficult to track

References

Oh's Intensive Care manual: Chapter 42  (pp. 487)  Acute  gastrointestinal  bleeding  by Joseph  JY  Sung

Gibson, Joanna A., and Robert D. Odze. "Pathology of diseases that cause upper gastrointestinal tract bleeding." Gastrointestinal Endoscopy Clinics 21.4 (2011): 583-596.

Baxter, M., and E. H. Aly. "Dieulafoy's lesion: current trends in diagnosis and management." The Annals of The Royal College of Surgeons of England 92.7 (2010): 548-554.

arcia-Tsao, Guadalupe, and Jaime Bosch. "Management of varices and variceal hemorrhage in cirrhosis." New England Journal of Medicine 362.9 (2010): 823-832.

Laursen, Stig Borbjerg, Jane Møller Hansen, and Ove B. Schaffalitzky De Muckadell. "The Glasgow Blatchford score is the most accurate assessment of patients with upper gastrointestinal hemorrhage." Clinical Gastroenterology and Hepatology 10.10 (2012): 1130-1135.

Hyett, Brian H., et al. "The AIMS65 score compared with the Glasgow-Blatchford score in predicting outcomes in upper GI bleeding." Gastrointestinal endoscopy 77.4 (2013): 551-557.

García-Pagán, Juan Carlos, et al. "Early use of TIPS in patients with cirrhosis and variceal bleeding." New England Journal of Medicine 362.25 (2010): 2370-2379.

Vlavianos, P., et al. "Balloon tamponade in variceal bleeding: use and misuse."BMJ: British Medical Journal 298.6681 (1989): 1158.

Reverter, Enric, and Juan Carlos García‐Pagán. "Management of an acute variceal bleeding episode." Clinical Liver Disease 1.5 (2012): 151-154.

Ioannou, G. N., J. Doust, and D. C. Rockey. "Terlipressin in acute oesophageal variceal haemorrhage." Alimentary pharmacology & therapeutics 17.1 (2003): 53-64.

Corley, Douglas A., et al. "Octreotide for acute esophageal variceal bleeding: a meta-analysis." Gastroenterology 120.4 (2001): 946-954.

Reiberger, Thomas, et al. "Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol." Gut62.11 (2013): 1634-1641.

Hou, Ming‐Chih, et al. "Antibiotic prophylaxis after endoscopic therapy prevents rebleeding in acute variceal hemorrhage: a randomized trial." Hepatology 39.3 (2004): 746-753.

Augustin, Salvador, Antonio González, and Joan Genescà. "Acute esophageal variceal bleeding: Current strategies and new perspectives." World J Hepatol 2.7 (2010): 261-274.

Chen, Ping-Hsien, et al. "Delayed endoscopy increases re-bleeding and mortality in patients with hematemesis and active esophageal variceal bleeding: a cohort study." Journal of hepatology 57.6 (2012): 1207-1213.

Kleber, Gerhard, et al. "Prediction of variceal hemorrhage in cirrhosis: a prospective follow-up study.Gastroenterology 100.5 (1991): 1332-1337.

Xu, Liang, et al. "Risk factors for predicting early variceal rebleeding after endoscopic variceal ligation." World journal of gastroenterology: WJG 17.28 (2011): 3347.

Tavakoli, Nader, et al. "Comparison of the efficacy of intravenous tranexamic acid with and without topical administration versus placebo in urgent endoscopy rate for acute gastrointestinal bleeding: A double-blind randomized controlled trial." United European Gastroenterology Journal (2017): 2050640617714940.

Barer, David, et al. "Cimetidine and tranexamic acid in the treatment of acute upper-gastrointestinal-tract bleeding." New England Journal of Medicine308.26 (1983): 1571-1575.

Brooks, W. Scott. "Use of Sucralfate in Variceal Sclerotherapy-Induced Ulcerations." Sucralfate (1995): 323-331.

Haruta, Ikuko, et al. "Balloon-occluded retrograde transvenous obliteration (BRTO), a promising nonsurgical therapy for ectopic varices: a case report of successful treatment of duodenal varices by BRTO." American Journal of Gastroenterology 91.12 (1996).

Park, Jonathan K., et al. "Balloon-occluded retrograde transvenous obliteration (BRTO) for treatment of gastric varices: review and meta-analysis." Digestive diseases and sciences 60.6 (2015): 1543.

Bosch, Jaime, et al. "Recombinant factor VIIa for variceal bleeding in patients with advanced cirrhosis: a randomized, controlled trial." Hepatology 47.5 (2008): 1604-1614.

Koch, Erica, et al. "Shock index in the emergency department: utility and limitations." Open Access Emergency Medicine (2019): 179-199.

Haffey, S., A. McKernan, and K. Pang. "Non-convulsive status epilepticus: a profile of patients diagnosed within a tertiary referral centre." Journal of Neurology, Neurosurgery & Psychiatry 75.7 (2004): 1043-1044.

Jirsch, J., and L. J. Hirsch. "Nonconvulsive seizures: developing a rational approach to the diagnosis and management in the critically ill population."Clinical neurophysiology 118.8 (2007): 1660-1670.

Rupprecht, Sven, et al. "Levetiracetam as a treatment option in non-convulsive status epilepticus." Epilepsy research 73.3 (2007): 238-244.

Misirocchi, Francesco, et al. "Prognostic value of Salzburg nonconvulsive status epilepticus criteria: The SACE score." Epilepsia 65.1 (2024): 138-147.

Shin, Jung-Won. "Management strategies for refractory status epilepticus." Journal of Neurocritical Care 16.2 (2023): 59-68.